NALP4 Antibody - BSA Free

Western Blot: NALP4 Antibody - BSA Free [NB100-56156] -

NLRP4 expression promotes pancreatic cancer cell proliferation.a Volcano plot showing the suppression of NLRP4 led to a greater susceptibility to olaparib in pancreatic cancer cell lines. b Immunoblot of NLRP4 in control and NLRP4-knockdown BxPC-3 and Capan-1 cells. BxPC-3 and Capan-1 cells were stably transfected with shNC, shNLRP4-1 and shNLRP4-2, and then MTS assays (c, d) and colony formation assays (e, f) were performed. ***p < 0.001. **p < 0.01. The analysis of significant differences was performed with Student’s t test. g–j Control and NLRP4-knockdown BxPC-3 and Capan-1 cells were injected into the left flank of nude mice. Tumor volumes were measured every 3 days. Tumors were harvested on day 21, photographed and weighed. Tumor weights are shown in (h), BxPC-3 tumor volumes are shown in (i), and Capan-1 tumor volumes are shown in (j). Data are shown as the mean +/- SD (n = 5). ***p < 0.001. The analysis of significant differences was performed with Student’s t test. ***p < 0.001. **p < 0.01. k, l Flow cytometry analysis of annexin V/7-ADD staining in the indicated cell lines. Data are presented as the mean +/- SD from three independent experiments. The analysis of significant differences was performed with Student’s t test. Image collected and cropped by CiteAb from the following open publication (https://www.nature.com/articles/s41419-024-06984-0), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: NALP4 Antibody - BSA Free [NB100-56156] -

Pancreatic cancer cells with high NLRP4 expression exhibit enhanced levels of autophagy in response to olaparib exposure.a–c Control or NLRP4-knockdown BxPC-3 and Capan-1 cells were treated with DMSO or olaparib (5 μM olaparib for BxPC-3 cells and 500 nM olaparib for Capan-1 cells) for 48 h. Western blotting analysis and quantification were performed. The analysis of significant differences was performed with Student's t test.**p < 0.01. d–f Effect of NLRP4 on the levels of autophagic flux. The mRFP-GFP-LC3 plasmid was transfected into the indicated cells for 24 h, and then the cells were treated with olaparib (5 μM olaparib for BxPC-3 cells and 500 nM olaparib for Capan-1 cells) for 48 h. Representative images were obtained by laser scanning confocal microscopy. The average fluorescence intensity of autophagic lysosomes (yellow dots in the merged images) and autophagic lysosomes (red in the merged images) in individual cells was quantified. Scale bar, 5 μm. The analysis of significant differences was performed with Student's t test. ***p < 0.001. g–i TEM-based ultrastructure analysis (autophagosomes) in the indicated cells. The analysis of significant differences was performed with Student’s t test. ***p < 0.001. Image collected and cropped by CiteAb from the following open publication (https://www.nature.com/articles/s41419-024-06984-0), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: NALP4 Antibody - BSA Free [NB100-56156] -

NLRP4 induces mitochondrial ROS generation in pancreatic cancer cells in response to olaparib exposure.a Cells treated with DMSO or olaparib (5 μM olaparib for BxPC-3 cells and 500 nM olaparib for Capan-1 cells) for 48 h were incubated with an ROS indicator. Representative images were obtained. b, c Cells treated with DMSO or olaparib (5 μM olaparib for BxPC-3 cells and 500 nM olaparib for Capan-1 cells) for 48 h were incubated with an ROS indicator, and fluorescence intensity was assessed with flow cytometry. The analysis of significant differences was performed with Student’s t test. ***p < 0.001. d, e Cells treated with DMSO or olaparib (5 μM olaparib for BxPC-3 cells and 500 nM olaparib for Capan-1 cells) for 48 h were incubated with JC-1 working solution, and fluorescence intensity was assessed with flow cytometry. The analysis of significant differences was performed with Student’s t test. ***p < 0.001. f–h Cells treated with olaparib (5 μM olaparib for BxPC-3 cells and 500 nM olaparib for Capan-1 cells) plus DMSO or MitoQ for 48 h were incubated with MitoSOX. Representative images were obtained, and the fluorescence intensity was assessed with flow cytometry. The analysis of significant differences was performed with Student’s t test. ***p < 0.001. i Changes in ROS-related genes in control and NLRP4-knockdown Capan-1 cells after olaparib treatment (500 nM olaparib for Capan-1 cells). Scale bar, 5 μm. j Western blotting analysis was performed for the indicated antibodies. Image collected and cropped by CiteAb from the following open publication (https://www.nature.com/articles/s41419-024-06984-0), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: NALP4 Antibody - BSA Free [NB100-56156] -

Complementation of NLRP4 rescues DNA repair defects and autophagy levels in NLRP4-knockdown pancreatic cancer cells and results in olaparib resistance.a Representative immunofluorescence micrographs of gamma-H2AX foci in the indicated cells with or without olaparib treatment (5 μM olaparib for BxPC-3 cells and 500 nM olaparib for Capan-1 cells). b TEM-based ultrastructure analysis (autophagosomes) in the indicated cells. c Cells were treated with DMSO or olaparib (5 μM olaparib for BxPC-3 cells and 500 nM olaparib for Capan-1 cells) for 48 h. Western blotting analysis was performed for the indicated antibodies. d, e Cells treated with DMSO or olaparib (5 μM olaparib for BxPC-3 cells and 500 nM olaparib for Capan-1 cells) for 48 h were incubated with an ROS indicator, and fluorescence intensity was assessed with flow cytometry. The analysis of significant differences was performed with one-way ANOVA. ***p < 0.001. f, g The indicated cells were treated with DMSO or olaparib (5 μM olaparib for BxPC-3 cells and 500 nM olaparib for Capan-1 cells). MTS assays were performed to investigate the effect of NLRP4 on olaparib resistance. The analysis of significant differences was performed with one-way ANOVA. ***p < 0.001. h Flow cytometry results for annexin V/7-ADD staining in the indicated cell lines after exposure to DMSO or olaparib (5 μM olaparib for BxPC-3 cells and 500 nM olaparib for Capan-1 cells). The analysis of significant differences was performed with Student’s t test. ***p < 0.001. i Schematic model showing that NLRP4 renders pancreatic cancer resistant to PARPi through the promotion of the DNA damage response and ROS-induced autophagy. Image collected and cropped by CiteAb from the following open publication (https://www.nature.com/articles/s41419-024-06984-0), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: NALP4 Antibody - BSA Free [NB100-56156] -

Identification of salivary exosomes in periodontitis patients and normal subjects. (A) Transmission electron microscopy of exosomes isolated from human saliva. Scale bar: 100 nm. (B) Exosomes concentration and size distribution by NanoSight analysis of human saliva. (C) Immunoblotting showed the exosomal membrane markers (ALIX, TSG101 CD63, CD9 and CD81), the intracellular protein Calnexin, the marker of autophagosome LC3 and markers of inflammasome (NLRP3 and NLRP4) in exosomes isolated from the saliva of one normal subject (case 01) and one periodontitis patient (case 02). Positive control for Calnexin was TE1 cells, and positive control for LC3 was TE1 cells after starvation for 6 h. Positive control for NLRP3 and NLRP4 was THP-1 cells. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/30923536), licensed under a CC-BY license. Not internally tested by Novus Biologicals.